397030.KQ AprilBio Co., Ltd. (에이프릴바이오) Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
00:51
Jan 28
Kim Hyeong-cheol CEO, Kim Hyung-chul Research Institute 815 Money Talk (815머니톡)
AprilBio gains analyst coverage momentum.
Biotech coverage by a specific Hankook Investment analyst is creating strong momentum. New coverage names can gap up, and AprilBio is his preferred name because Daishin and others are initiating coverage and target levels could trigger further upside.
MED
03:10
Jan 22
Biotech tech-transfer momentum stays strong
Although Alteogen's royalty miss hurt bio sentiment, biotech moves on individual issues and technology-transfer momentum remains strong; ABL Bio, D&D Pharmatech, Orum Therapeutics, Alzinomics, and April Bio are worth watching.
397030.KQ
MED

About 397030.KQ Investor Commentary

Across the available history and selected sources, Buzzberg tracks 397030.KQ (AprilBio Co., Ltd. (에이프릴바이오)) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Kim Hyeong-cheol, Lee Yoon-hee.